Fresenius SE & Co. KGaA

Earnings Release • Jun 11, 2012

News Details

Ad-hoc | 11 June 2012 10:38

Fresenius SE & Co. KGaA: Fresenius raises 2012 outlook – Fresenius Kabi exceeding expectations

Fresenius SE & Co. KGaA / Key word(s): Change in Forecast/Miscellaneous

11.06.2012 10:38

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---

Fresenius raises 2012 outlook - Fresenius Kabi exceeding expectations

With ongoing strong growth in all Group business segments and Fresenius
Kabi exceeding previous forecasts, Fresenius raises its guidance for 2012.

Fresenius Group now expects net income* to increase by 14% to 16% and
sales** by 12% to 14%, both in constant currency and before effects of the
announced Rhön-Klinikum AG acquisition. Previously, the Company projected
net income growth of 12% to 15% and sales growth at the upper end of a 10%
to 13% range, both in constant currency.

In the first months of 2012, Fresenius Kabi has recorded substantial
organic revenue growth across all regions and product segments, exceeding
earlier expectations. Particularly in the U.S., revenue growth has been
materially stronger than initially projected mainly due to ongoing IV drug
shortages, including Propofol, which may continue well into the third
quarter.

As a result, Fresenius Kabi raises its outlook for 2012. The company now
expects organic sales growth of 7% to 9% and an EBIT margin between 20% and
20.5%. Previously, Fresenius Kabi projected organic sales growth of 6% to
8% and an EBIT margin at the upper end of a 19.5% to 20% range.

* Net income attributable to shareholders of Fresenius SE & Co. KGaA -
adjusted for a non-taxable investment gain of EUR30 million at Fresenius
Medical Care; 2011 adjusted for the effects of mark-to-market accounting of
the Mandatory Exchangeable Bonds and the Contingent Value Rights.

** Previous year's sales were adjusted according to a U.S. GAAP accounting
change. The sales adjustment of -EUR161 million for the full year 2011
solely relates to Fresenius Medical Care North America.

(Financial statements according to U.S. GAAP)

Fresenius SE & Co. KGaA,
represented by Fresenius Management SE,
Board of Management

Bad Homburg v.d.H., June 11, 2012

End of note

11.06.2012 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language: English
Company: Fresenius SE & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg v.d.H.
Germany
Phone: +49 (0)6172 608-2485
Fax: +49 (0)6172 608-2488
E-mail: ir-fre@fresenius.com
Internet: www.fresenius.com
ISIN: DE0005785604
WKN: 578560
Indices: DAX
Listed: Regulierter Markt in Düsseldorf, Frankfurt (Prime Standard),
München; Freiverkehr in Berlin, Hamburg, Hannover, Stuttgart;
Terminbörse EUREX

End of Announcement DGAP News-Service

---